ArticlePloS one2012
Soluble serum CD81 is elevated in patients with chronic hepatitis C and correlates with alanine aminotransferase serum activity.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 97 citations in OpenAlex.
- The diagnostic potential of extracellular vesicles in virus-related diseases.Frontiers in cellular and infection microbiology · 2025Review
- Relationship between exosomes and cancer: formation, diagnosis, and treatment.International journal of biological sciences · 2025Review
- Exosome-based therapies for inflammatory disorders: a review of recent advances.Stem cell research & therapy · 2024Review
- Extracellular Vesicles in Viral Liver Diseases.Viruses · 2024Review
- Emerging role of exosomes as a liquid biopsy tool for diagnosis, prognosis & monitoring treatment response of communicable & non-communicable diseases.The Indian journal of medical research · 2024Review
- Composition, functions, and applications of exosomal membrane proteins.Frontiers in immunology · 2024Review
- Exosome Mediated Cell-Cell Crosstalk in Tissue Injury and Repair.Results and problems in cell differentiation · 2024Review
- Liquid Liver Biopsy for Disease Diagnosis and Prognosis.Journal of clinical and translational hepatology · 2023Review
- The emerging role of medical foods and therapeutic potential of medical food-derived exosomes.Nanoscale advances · 2023Review
- Changes in Soluble Serum CD81 Concentration during an Oral Glucose Tolerance Test in Patients with Diabetes Mellitus and Individuals with Normal Glucose Tolerance.Diagnostics (Basel, Switzerland) · 2023Article
- Extracellular Vesicles as a Translational Approach for the Treatment of COVID-19 Disease: An Updated Overview.Viruses · 2023Review
- Renal CD81 interacts with sodium potassium 2 chloride cotransporter and sodium chloride cotransporter in rats with lipopolysaccharide-induced preeclampsia.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023Article
- Exosomes─Nature's Lipid Nanoparticles, a Rising Star in Drug Delivery and Diagnostics.ACS nano · 2022Review
- Small extracellular vesicles and liver diseases: From diagnosis to therapy.World journal of hepatology · 2022Review
- Integrated view of molecular diagnosis and prognosis of dengue viral infection: future prospect of exosomes biomarkers.Molecular and cellular biochemistry · 2022Review
- Exosomes: Emerging implementation of nanotechnology for detecting and managing novel corona virus- SARS-CoV-2.Asian journal of pharmaceutical sciences · 2022Review
- Update on the application of mesenchymal stem cell-derived exosomes in the treatment of Parkinson's disease: A systematic review.Frontiers in neurology · 2022Review
- Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications.ACS biomaterials science & engineering · 2021Review
- Clinical applications for exosomes: Are we there yet?British journal of pharmacology · 2021Review
- Recent Progress on Exosomes in RNA Virus Infection.Viruses · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimCellular CD81 is a well characterized hepatitis C virus (HCV) entry factor, while the relevance of soluble exosomal CD81 in HCV pathogenesis is poorly defined. We performed a case-control study to investigate whether soluble CD81 in the exosomal serum fraction is associated with HCV replication and inflammatory activity. PATIENTS AND
methodsFour cohorts were investigated, patients with chronic hepatitis C (n = 37), patients with chronic HCV infection and persistently normal ALT levels (n = 24), patients with long term sustained virologic response (SVR, n = 7), and healthy volunteers (n = 23). Concentration of soluble CD81 was assessed semi-quantitatively after differential centrifugation ranging from 200 g to 100,000 g in the fifth centrifugation fraction by immunoblotting and densitometry.
resultsSoluble CD81 was increased in patients with chronic hepatitis C compared to healthy subjects (p = 0.03) and cured patients (p = 0.017). Patients with chronic HCV infection and persistently normal ALT levels and patients with long term SVR had similar soluble CD81 levels as healthy controls (p>0.2). Overall, soluble CD81 levels were associated with ALT levels (r = 0.334, p = 0.016) and severe liver fibrosis (p = 0.027).
conclusionCD81 is increased in the exosomal serum fraction in patients with chronic hepatitis C and appears to be associated with inflammatory activity and severity of fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.